PE20080838A1 - Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos - Google Patents

Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos

Info

Publication number
PE20080838A1
PE20080838A1 PE2007000968A PE2007000968A PE20080838A1 PE 20080838 A1 PE20080838 A1 PE 20080838A1 PE 2007000968 A PE2007000968 A PE 2007000968A PE 2007000968 A PE2007000968 A PE 2007000968A PE 20080838 A1 PE20080838 A1 PE 20080838A1
Authority
PE
Peru
Prior art keywords
modulators
processes
crystalline forms
chemokine receptor
receptor activity
Prior art date
Application number
PE2007000968A
Other languages
English (en)
Spanish (es)
Inventor
Michael G Yang
Robert J Cherney
Martin G Eastgate
Jale Muslehiddinoglu
Siva Josyula Prasad
Zili Xiao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38823540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080838(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20080838A1 publication Critical patent/PE20080838A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
PE2007000968A 2006-07-28 2007-07-26 Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos PE20080838A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83423506P 2006-07-28 2006-07-28
US89602607P 2007-03-21 2007-03-21
US11/782,704 US7671062B2 (en) 2006-07-28 2007-07-25 Modulators of chemokine receptor activity, crystalline forms and process

Publications (1)

Publication Number Publication Date
PE20080838A1 true PE20080838A1 (es) 2008-06-14

Family

ID=38823540

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000968A PE20080838A1 (es) 2006-07-28 2007-07-26 Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos

Country Status (29)

Country Link
US (1) US7671062B2 (enExample)
EP (2) EP2184283A1 (enExample)
JP (1) JP2009544758A (enExample)
KR (1) KR20090035036A (enExample)
CN (1) CN101511822A (enExample)
AR (1) AR062114A1 (enExample)
AT (1) ATE471928T1 (enExample)
AU (1) AU2007279256A1 (enExample)
BR (1) BRPI0715066A2 (enExample)
CA (1) CA2659259A1 (enExample)
CL (3) CL2007002194A1 (enExample)
CO (1) CO6190527A2 (enExample)
CY (1) CY1110785T1 (enExample)
DE (1) DE602007007335D1 (enExample)
DK (1) DK2049477T3 (enExample)
EA (1) EA014960B1 (enExample)
ES (1) ES2346591T3 (enExample)
HR (1) HRP20100371T1 (enExample)
IL (1) IL196518A0 (enExample)
MX (1) MX2009000803A (enExample)
NO (1) NO20090256L (enExample)
NZ (1) NZ574656A (enExample)
PE (1) PE20080838A1 (enExample)
PL (1) PL2049477T3 (enExample)
PT (1) PT2049477E (enExample)
SG (1) SG158925A1 (enExample)
SI (1) SI2049477T1 (enExample)
TW (1) TW200823203A (enExample)
WO (1) WO2008014381A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687508B2 (en) * 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
SMT202200088T1 (it) * 2017-07-20 2022-03-21 Bristol Myers Squibb Co Procedimento per la preparazione di n-((1r,2s,sr)-5-(tert-butilammino)-2-((s)-3-(7-tert-butilpirazolo[1,5-a][1,3,5]triazin-4-ilammino)-2-ossopirrolidin-1-il)cicloesil)acetammide
EP3687525B1 (en) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN115494184B (zh) * 2022-05-09 2023-07-28 浙江海正药业股份有限公司 一种同时检测药物中异丙苯磺酸甲酯、异丙苯磺酸乙酯的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6383082A (ja) 1986-09-26 1988-04-13 Takeda Chem Ind Ltd テトラヒドロフランカルボン酸誘導体の製造法
CA2084800A1 (en) 1991-12-16 1993-06-17 Joseph P. Vacca Hiv protease inhibitors with an internal lactam ring
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6054579A (en) 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
EP1051397B1 (en) 1998-01-29 2008-12-31 Aventis Pharmaceuticals Inc. Method for preparing an n- (aliphatic or aromatic)carbonyl -2-aminoacetamide compound and a cyclyzed compound
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
WO2001017992A1 (en) 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
AR035773A1 (es) 2000-12-20 2004-07-14 Bristol Myers Squibb Pharma Co Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina
CA2432908A1 (en) 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Company Diamines as modulators of chemokine receptor activity
AU2002249103A1 (en) 2001-03-29 2002-10-15 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
GB0114867D0 (en) 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
DE10135043A1 (de) 2001-07-11 2003-01-30 Bayer Cropscience Gmbh Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren
EP1483241A4 (en) 2002-03-08 2006-12-13 Bristol Myers Squibb Co CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2004071449A2 (en) 2003-02-12 2004-08-26 Bristol-Myers Squibb Company Lactams as modulators of chemokine receptor activity
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
WO2004110376A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Ccr-2 antagonists for treatment of neuropathic pain
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US7863317B2 (en) 2003-08-21 2011-01-04 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US20050043392A1 (en) 2003-08-21 2005-02-24 Carter Percy H. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
WO2006013427A2 (en) 2004-07-30 2006-02-09 Pfizer Products Inc. Treatment of ccr2 mediated diseases or disorders
KR20070063562A (ko) 2004-09-28 2007-06-19 얀센 파마슈티카 엔.브이. 치환 디피페리딘 ｃｃｒ２ 길항제

Also Published As

Publication number Publication date
CA2659259A1 (en) 2008-01-31
TW200823203A (en) 2008-06-01
CL2007002196A1 (es) 2008-05-30
BRPI0715066A2 (pt) 2013-05-28
IL196518A0 (en) 2009-11-18
SG158925A1 (en) 2010-02-26
PT2049477E (pt) 2010-08-27
SI2049477T1 (sl) 2010-09-30
PL2049477T3 (pl) 2010-11-30
EA014960B1 (ru) 2011-04-29
WO2008014381A3 (en) 2008-12-31
CO6190527A2 (es) 2010-08-19
EP2049477A2 (en) 2009-04-22
DE602007007335D1 (de) 2010-08-05
HK1125931A1 (en) 2009-08-21
CN101511822A (zh) 2009-08-19
AU2007279256A1 (en) 2008-01-31
CY1110785T1 (el) 2015-06-10
US20080027083A1 (en) 2008-01-31
MX2009000803A (es) 2009-01-29
KR20090035036A (ko) 2009-04-08
WO2008014381A2 (en) 2008-01-31
JP2009544758A (ja) 2009-12-17
ES2346591T3 (es) 2010-10-18
CL2007002195A1 (es) 2008-02-08
NO20090256L (no) 2009-02-25
EA200900244A1 (ru) 2009-08-28
US7671062B2 (en) 2010-03-02
CL2007002194A1 (es) 2008-02-08
EP2184283A1 (en) 2010-05-12
AR062114A1 (es) 2008-10-15
NZ574656A (en) 2011-12-22
DK2049477T3 (da) 2010-10-25
ATE471928T1 (de) 2010-07-15
HRP20100371T1 (hr) 2010-08-31
EP2049477B1 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
CL2011000795A1 (es) Compuestos derivados de n-(1,3,4-tiadiazol-2-il) aril/heteroaril-amida, agonistas del receptor de 1-fosfato de esfingosina; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratammiento de enfermedades autoinmunes, inflamatorias cronicas, rechazo de transplantes, dolor, entre otras.
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2008001122A1 (es) Compuestos derivados de imidazo[1,2,3-ij]-1,8-naftiridin-4,9-diona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
MA50817B1 (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
CR10699A (es) Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt
CL2013003715A1 (es) Compuestos derivados de heterociclos nitrogenados, antagonistas trpm8; composicion farmaceutica; y su uso en el tratamiento de la migraña, dolor agudo, inflamatorio o neuropatico, entre otros
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
CL2007001090A1 (es) Compuestos derivados de diazepano, antagonistas de los receptores ccr-2, ccr-5 y ccr-3; procedimiento de preparacion; composicion farmaceutica; compuesto intermediario; y uso del compuesto en el tratamiento de una enfermedad oclusiva de arterias perifericas, isquemia critica de extremidades, angina inestable, apoplejia, entre otras
PE20121349A1 (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
CL2007002195A1 (es) Compuesto n-((1r,2s,5r)-5-(isopropil(metil)amino)-2-((s)-2-oxo-3-(6-(trifluorometil)quinazolin-4-ilamino)pirrolidin-1-il)ciclohexil)acetamida; forma cristalina del compuesto; composicion farmaceutica; y uso en el tratamiento de enfermedades tales com
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
UY35275A (es) Derivados de aminopirazina
PE20081308A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
ECSP088761A (es) Nuevas combinaciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos
CL2007003556A1 (es) Compuestos derivados de 6-(piperidin-4-ilamino)piridazin-3-carbonitrilos, antagonistas del receptor de dopamina 2 de rapida disociacion; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el
EP3694629A4 (en) COMPOSITION OF UREA FOR USE IN THE PRODUCTION OF Lye
PE20090367A1 (es) Formas cristalinas a y b del compuesto 3-(2r-tetrahidrofuril-metil)-2-tioxantina
PE20100467A1 (es) Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen
CL2013003567A1 (es) Forma cristalina anhidra de {(s)-3-[6-(6-metoxi-5-metil-piridin-3-il)-5,6,7,8-tetrahidro-pirido[4,3-d]pirimidin-4-iloxi]-pirrolidin-1-il}-(tetrahidro-piran-4-il)-metanona, sales de la misma; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos autoinmunes, inflamatorios, alergicos, rechazo de trasplantes, entre otros.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed